4.05
0.15 (3.85%)
| Previous Close | 3.90 |
| Open | 3.82 |
| Volume | 493,355 |
| Avg. Volume (3M) | 188,185 |
| Market Cap | 590,861,504 |
| Price / Sales | 22.31 |
| Price / Book | 2.10 |
| 52 Weeks Range | |
| Earnings Date | 29 Sep 2025 |
| Operating Margin (TTM) | -384.43% |
| Diluted EPS (TTM) | -3.63 |
| Quarterly Revenue Growth (YOY) | -29.90% |
| Current Ratio (MRQ) | 0.920 |
| Operating Cash Flow (TTM) | -85.93 M |
| Levered Free Cash Flow (TTM) | -56.25 M |
| Return on Assets (TTM) | -63.60% |
| Return on Equity (TTM) | -1,642.75% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Inventiva S.A. - American Depos | Bearish | Mixed |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -0.5 |
| Average | -0.13 |
|
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Institutions | 5.09% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 26.00 (Piper Sandler, 541.98%) | Buy |
| Median | 20.00 (393.83%) | |
| Low | 11.00 (Guggenheim, 171.61%) | Buy |
| Average | 18.80 (364.20%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 4.95 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 18 Nov 2025 | 11.00 (171.60%) | Buy | 4.00 |
| 02 Sep 2025 | 13.00 (220.99%) | Buy | 5.26 | |
| Wolfe Research | 06 Nov 2025 | 13.00 (220.99%) | Buy | 4.18 |
| HC Wainwright & Co. | 09 Oct 2025 | 24.00 (492.59%) | Buy | 5.53 |
| 03 Sep 2025 | 20.00 (393.83%) | Buy | 5.77 | |
| Canaccord Genuity | 30 Sep 2025 | 20.00 (393.83%) | Buy | 5.79 |
| Piper Sandler | 27 Aug 2025 | 26.00 (541.98%) | Buy | 5.23 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |